Avalo Therapeutics (AVTX) Equity Average (2016 - 2025)
Historic Equity Average for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to $98.1 million.
- Avalo Therapeutics' Equity Average rose 252615.16% to $98.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.1 million, marking a year-over-year increase of 252615.16%. This contributed to the annual value of $70.2 million for FY2024, which is 398634.73% up from last year.
- According to the latest figures from Q3 2025, Avalo Therapeutics' Equity Average is $98.1 million, which was up 252615.16% from $113.6 million recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Equity Average registered a high of $127.8 million during Q1 2025, and its lowest value of -$63.1 million during Q2 2024.
- Over the past 5 years, Avalo Therapeutics' median Equity Average value was $11.0 million (recorded in 2023), while the average stood at $22.5 million.
- In the last 5 years, Avalo Therapeutics' Equity Average tumbled by 347653.06% in 2023 and then surged by 252615.16% in 2025.
- Over the past 5 years, Avalo Therapeutics' Equity Average (Quarter) stood at $31.7 million in 2021, then tumbled by 120.42% to -$6.5 million in 2022, then soared by 269.97% to $11.0 million in 2023, then surged by 600.52% to $77.1 million in 2024, then increased by 27.26% to $98.1 million in 2025.
- Its Equity Average was $98.1 million in Q3 2025, compared to $113.6 million in Q2 2025 and $127.8 million in Q1 2025.